ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced that the European Commission has authorised Vocabria (cabotegravir ...

The sneak peek gives a glimpse inside the headline-making incident that led to Moore’s early departure from Season 16.

NATCO Pharma said that it has received approval of its ANDA for Everolimus tablets for oral suspension (TFOS), a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation.

Lupin has received USFDA approval to market a generic HIV medication in the US market, under the PEPFAR program. The drug ...

As part of the regulatory action, memantine/donepezil extended-release capsules have been granted a 180-day exclusivity in ...

Net interest income increases 9.8% to Rs 7,196.3 crore Vs Rs 6,553.5 crore Provisions and contingencies zoom 37.1% to Rs ...

Miami went 3-4 in those contests. And when the suspension was issued, it wasn't clear if Butler would play for Miami ever again. But with no trade in place — and evidently without one in the ...

Samsung’s Galaxy Book4 Pro brings — with the exception of the graphics card — premium hardware to make a quality, touchable (and pen-able, if you purchase an S Pen separately) 2-in-1 ...

The Baldur's Gate 3 Sarin skeleton puzzle is one you find while roaming the sewers and cisterns of the city proper in Act 3. In the centre of the underground region, you'll encounter Aelis ...

'ZDNET Recommends': What exactly does it mean? ZDNET's recommendations are based on many hours of testing, research, and comparison shopping. We gather data from the best available sources ...

The dye is known as erythrosine, FD&C Red No. 3 or Red 3. The ban removes it from the list of approved color additives in foods, dietary supplements and oral medicines, such as cough syrups. More than ...

In her State of the State address, Hochul also announced a new tax cut plan to reduce taxes for over 8.3 million New Yorkers. The program will affect joint filers making under $323,000 per year ...